Seminars in Oncology
Volume 31, Issue 1 , Pages 33-36 , February 2004

Nonmyeloablative reduced-intensity transplantation in multiple myeloma

  • Athanasios Anagnastopoulos

      Affiliations

    • Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Ana Aleman

      Affiliations

    • Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Sergio Giralt

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Sergio Giralt, MD, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

References 

  1. Gale RP, Champlin RE. How does bone marrow transplantation cure leukemia?. Lancet. 1984;2:28–30
  2. Horowitz M, Gale R, Sondel PM, et al.  Graft-versus leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  3. Goldman J, Gale R, Horowitz MM, et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase (increased risk of relapse associated with T-cell depletion). Ann Intern Med. 1988;108:806–814
  4. Gale RP, Horowitz MM, Ash RC, et al.  Identical twin bone marrow transplantation for leukemia. Ann Intern Med. 1994;120:646–652
  5. Weiden P, Flournoy N, Thomas E, et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068–1073
  6. Weiden P, Sullivan K, Flournoy N, et al.  Antileukemic effect of chronic graft-versus host disease (contribution to improved survival after allogeneic marrow transplantation). N Engl J Med. 1981;304:1529–1532
  7. Sullivan K, Storb R, Bucker CD, et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320:828–834
  8. Kolb HJ, Schattenberg A, Goldman JM, et al.  Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood. 1995;86:2041–2050
  9. Collins RH, Shpilberg O, Drobyski WR, et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  10. Tricot G, Vesole D, Jagannath S, et al.  Graft-versus-myeloma effect (Proof of principle). Blood. 1996;87:1196–1198
  11. Lokhorst H, Schattenberg A, Cornelissen J, et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206–4211
  12. Salama M, Nevill T, Marcellus D, et al.  Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000;26:1179–1184
  13. Gahrton G, Svensson H, Bjorkstrand B, et al.  Syngeneic transplantation in multiple myeloma—A case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1999;24:741–745
  14. Bjorkstrand B, Ljungman P, Svensson H, et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma (A retrospective case-matched study from the European Group for Blood and Marrow Transplantation). Blood. 1996;88:4711–4718
  15. Lokhorst H, Segeren C, Holt B, et al.  T cell depleted allogeneic stem cell transplantation as part of first line treatment of multiple myeloma is inferior to intensive treatment alone. Result from prospective donor versus no comparison in patients treated in the Horon 24 Study. Blood. 2001;98:487a; (abstr)
  16. Ringden O, Horowitz M, Gale R, et al.  Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA. 1993;270:57–60
  17. Cahn J, Labopin M, Mandelli F, et al.  Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years (A retrospective analysis of the European Bone Marrow Transplant Group). Blood. 1995;85:575–579
  18. Gale R, Bortin M, Van Bekkum D, et al.  Risk factors for acute graft versus host disease. Br J Haematol. 1987;67:397–406
  19. Ferrara J, Deeg H. Graft versus host disease. N Engl J Med. 1991;324:667–674
  20. Holler E, Kolb H, Moller A, et al.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  21. Holler E, Kolb H, Wilmanns W. Treatment of GVHD-TNF-antibodies and related antagonists. Bone Marrow Transplant. 1993;12(suppl 3):29–31
  22. Xun C, Thompson J, Jenning C, et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994;83:2360–2367
  23. Fahey J, Schnelle J, Boscardin J, et al.  Distinct categories of immunologic changes in frail elderly. Mech Ageing Dev. 2000;115:1–20
  24. Albright J, Albright J. Soluble receptors and other substances that regulate proinflammatory cytokines in young and aging humans. J Gerontol. 2000;55:B20–B25
  25. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (Harnessing graft versus-leukemia without myeloablative therapy). Blood. 1997;89:4531–4536
  26. Slavin S, Nagler A, Naparstak E, et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood. 1998;91:756–763
  27. Khouri I, Keating MJ, Korbling M, et al.  Transplant lite (Induction of graft vs malignancy using fludarabine based non-ablative chemotherapy and allogeneic progenitor-cell transplantation as treatment for lymphoid malignancies). J Clin Oncol. 1998;16:2817–2824
  28. Champlin R, Khouri I, Kornblau J, et al.  Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft versus malignancy effect. Oncology. 1999;13:621–626
  29. Giralt S, Weber D, Cohen A, et al.  Non-myeloablative conditioning with fludarabine (F)/melphalan (M) for patients with multiple myeloma (MM). Proc Am Soc Clin Oncol. 1999;18:6a; (abstr 18)
  30. Storb R, Yu C, Wagner J, et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  31. Storb R, Yu C, Barnett T, et al.  Stable mixed hematopoietic chimerism in dog leukocyte antigen identical littermate dogs given lymph node irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1999;94:1131–1136
  32. McSweeney P, Niederwieser D, Shizuru J, et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies (Replacing high-dose cytotoxic therapy with graft-versus-tumor effects). Blood. 2001;97:3390–3400
  33. Molina A, Sahebi F, Maloney D, et al.  Non-myeloablative peripheral blood stem cell allografts (PBSC) following cytoreductive autotransplants for treatment of multiple myeloma (MM). Blood. 2000;96:480a; (abstr)
  34. Lalancette M, Rezvani K, Szydlo R, et al.  Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma (The EBMT experience). Blood. 2000;96:204a; (abstr)
  35. Peggs K, Williams C, Chopra R, et al.  Non-myeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma. Blood. 2000;96:781a; (abstr)
  36. Schaefer H, Bader P, Hebart H, et al.  Mini-allografts as salvage therapy in patients with heavily pretreated multiple myeloma. Blood. 2000;96:306b; (abstr)
  37. Badros A, Tricot G, Morris C, et al.  Significant graft vs myeloma effect after non-myeloablative allogeneic transplantation in multiple myeloma. Blood. 2000;96:352b; (abstr)
  38. Alexanian R, Dimopoulos A. Drug therapy (The treatment of multiple myeloma). N Engl J Med. 1994;330:484–489

PII: S0093-7754(03)00562-1

doi: 10.1053/j.seminoncol.2003.10.019

Seminars in Oncology
Volume 31, Issue 1 , Pages 33-36 , February 2004

Article Tools